Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gazyva

- PMLiVE

Data backs up Roche’s Tecentriq/Avastin combo in lung cancer

Results will be used to pursue a first-line indication in NSCLC

- PMLiVE

Mylan gets first biosimilar Herceptin OK from FDA

Ogivri approved by US regulators for all of Roche blockbuster's indications

- PMLiVE

Roche offers diabetes digital health programme to UK patients

Partners with OurPath for its six-week lifestyle management programme

- PMLiVE

First Herceptin biosimilar cleared in Europe

Ontruzant is approved for all the same indications as Roche’s blockbuster

- PMLiVE

Lung cancer data gives Roche’s Tecentriq a boost

Will help its PD-L1 inhibitor compete with Merck & Co’s Keytruda

Roche Basel Switzerland

New data could unlock bigger market for Roche’s Hemlibra

Trial shows it ‘significantly’ reduced bleeds in some haemophilia A patients

Roche acquires US laboratory big data company Viewics

Gains cloud-based laboratory business analytics capabilities

Roche Basel Switzerland

Roche gets first approval for haemophilia A therapy

The first-in-class therapy wins US marketing licence three months earlier than expected

Roche Basel Switzerland

Roche gets FDA OKs for Alecensa and Zelboraf

Gains US licences for first-line use in lung cancer and a rare blood cancer

Roche Basel Switzerland

Smartphone monitoring shows its worth in Roche MS trial

The tool uses smartphone sensors to measure neurological tests

Roche Basel Switzerland

Roche biggest pharma R&D spender in PwC survey

Pharma giant on track to spend 21.9% of its total revenue on research this year

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links